Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Isoglycyrrhizinate for Acute Drug-induced Liver Injury
NCT02734966Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Magnesium isoglycyrrhizinate in drug induced liver injury (DILI) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Rate of ALT normalization at 4 weeks. Started Dec 2007; status: completed.
02
Drugs
Magnesium isoglycyrrhizinate
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT02734966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02734966.